File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1080/16078454.2019.1637574
- Scopus: eid_2-s2.0-85069289167
- PMID: 31280705
- WOS: WOS:000474221100001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Ficolled bone marrow is superior to bone marrow buffy coat for detection of minimal residual disease in multiple myeloma
Title | Ficolled bone marrow is superior to bone marrow buffy coat for detection of minimal residual disease in multiple myeloma |
---|---|
Authors | |
Keywords | ASO RQ-PCR Bone marrow buffy coat Ficolled bone marrow Minimal residual disease Multiple myeloma Red cell lysis Sample preparation Sensitivity |
Issue Date | 2019 |
Publisher | Taylor & Francis. The Journal's web site is located at http://www.tandfonline.com/loi/yhem20 |
Citation | Hematology, 2019, v. 24 n. 1, p. 533-537 How to Cite? |
Abstract | Objective:
Buffy coat and ficoll of bone marrow (BM) are viable options for the study of minimal residual disease (MRD) in multiple myeloma (MM). As yet, there is no data about the superiority of either sample types. Herein, we aimed to address this issue.
Methods:
Forty pairs of ficolled BMs and BM buffy coats of 19 MM patients were studied for MRD by allele-specific oligonucleotide real-time quantitative PCR, with patient-specific primers/probes whenever appropriate.
Results:
There were 41 pairs of MRD data for comparison analysis due to one patient with biclonal disease. MRD levels in ficolls and buffy coats were highly concordant (rs = 0.936, P < 0.0001), with 31 (76%) and seven (17%) pairs being concomitantly MRD-positive or -negative. On the other hand, apart from the 16 pairs being both MRD-negative, or -positive but not quantifiable in ficolls and buffy coats, majority (n = 22, 88%) had higher MRD levels in ficolled BMs than BM buffy coats. Furthermore, in 17 pairs, in which MRD was quantifiable in both, MRD levels in ficolled BMs were 3.1 times those of BM buffy coats (median, 567/105 vs. 184/105, P = 0.001).
Conclusion:
Taken together, ficolled BM is more sensitive than BM buffy coat for MRD detection in MM, hence should be recommended. |
Persistent Identifier | http://hdl.handle.net/10722/272286 |
ISSN | 2023 Impact Factor: 2.0 2023 SCImago Journal Rankings: 0.543 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bai, Y | - |
dc.contributor.author | Chim, CS | - |
dc.date.accessioned | 2019-07-20T10:39:18Z | - |
dc.date.available | 2019-07-20T10:39:18Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Hematology, 2019, v. 24 n. 1, p. 533-537 | - |
dc.identifier.issn | 1024-5332 | - |
dc.identifier.uri | http://hdl.handle.net/10722/272286 | - |
dc.description.abstract | Objective: Buffy coat and ficoll of bone marrow (BM) are viable options for the study of minimal residual disease (MRD) in multiple myeloma (MM). As yet, there is no data about the superiority of either sample types. Herein, we aimed to address this issue. Methods: Forty pairs of ficolled BMs and BM buffy coats of 19 MM patients were studied for MRD by allele-specific oligonucleotide real-time quantitative PCR, with patient-specific primers/probes whenever appropriate. Results: There were 41 pairs of MRD data for comparison analysis due to one patient with biclonal disease. MRD levels in ficolls and buffy coats were highly concordant (rs = 0.936, P < 0.0001), with 31 (76%) and seven (17%) pairs being concomitantly MRD-positive or -negative. On the other hand, apart from the 16 pairs being both MRD-negative, or -positive but not quantifiable in ficolls and buffy coats, majority (n = 22, 88%) had higher MRD levels in ficolled BMs than BM buffy coats. Furthermore, in 17 pairs, in which MRD was quantifiable in both, MRD levels in ficolled BMs were 3.1 times those of BM buffy coats (median, 567/105 vs. 184/105, P = 0.001). Conclusion: Taken together, ficolled BM is more sensitive than BM buffy coat for MRD detection in MM, hence should be recommended. | - |
dc.language | eng | - |
dc.publisher | Taylor & Francis. The Journal's web site is located at http://www.tandfonline.com/loi/yhem20 | - |
dc.relation.ispartof | Hematology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | ASO RQ-PCR | - |
dc.subject | Bone marrow buffy coat | - |
dc.subject | Ficolled bone marrow | - |
dc.subject | Minimal residual disease | - |
dc.subject | Multiple myeloma | - |
dc.subject | Red cell lysis | - |
dc.subject | Sample preparation | - |
dc.subject | Sensitivity | - |
dc.title | Ficolled bone marrow is superior to bone marrow buffy coat for detection of minimal residual disease in multiple myeloma | - |
dc.type | Article | - |
dc.identifier.email | Chim, CS: jcschim@hku.hk | - |
dc.identifier.authority | Chim, CS=rp00408 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1080/16078454.2019.1637574 | - |
dc.identifier.pmid | 31280705 | - |
dc.identifier.scopus | eid_2-s2.0-85069289167 | - |
dc.identifier.hkuros | 299536 | - |
dc.identifier.volume | 24 | - |
dc.identifier.issue | 1 | - |
dc.identifier.spage | 533 | - |
dc.identifier.epage | 537 | - |
dc.identifier.isi | WOS:000474221100001 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 1024-5332 | - |